pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Tevimbra
drug · antibody
save

Tevimbra

Phase 3updated 6mo ago
by $ONC BeOne Medicines Ltd.🔗 ChEMBL
Phase 3
community read0 votes

🐶 often sniffed alongside

top 1
  • tagApproval48 co-mentions · 12 sources

Antibody drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 50 investigational indications.

indications

indications
NSCLC

targets

Programmed cell death protein 1

all catalysts(0)

nothing on the calendar yet

News(10)

  • China has a clear shot to 2030 goals, though economic, cultural barriers remain
    To grow into a biopharma juggernaut, China aims to become the leading source of innovative medicines on the global markets—a goal that experts say the country is on track to hit.
    biospace · 6d ago
  • 6 potential blockbusters that could pave China’s path to 2030 ambitions
    In its latest five-year plan, China has set its sights on developing five drugs that could each rake in more than $1 billion globally by 2030. Experts say it's well on its way, with two medications…
    biospace · 13d ago
  • 5 biggest venture capital raises of Q3 2026
    Venture capital continued to flow into biopharma in the third quarter, though experts pointed out that investors remained selective, preferring to put their money behind advanced and derisked asset…
    biospace · 1mo ago
  • Solstice rises with $225M to develop next-gen CTLA-4 drug from China
    Solstice Oncology, founded in February, is emerging from stealth having already secured an investigational new drug application from the FDA for a Phase 2 trial of a CTLA-4 antibody purchased from…
    biospace · 2mo ago
  • Mid-cap biotechs join Trump’s latest round of drug pricing deals
    Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.
    biopharma_dive · 2mo ago
  • Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ Ziihera
    Gastroesophageal adenocarcinoma presents the biggest market opportunity for Jazz Pharmaceuticals’ Ziihera, according to Truist Securities, which forecasts peak sales of the drug to reach $2.5 billion.
    biospace · 2mo ago
  • New Jazz cancer drug approval could drive blockbuster sales
    Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.
    biopharma_dive · 2mo ago
  • Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
    Summit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be requir…
    biospace · 3mo ago
  • Akeso, Summit drug extends survival in closely watched lung cancer trial
    Though ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study, the total survival benefit of four months stirred debate and pressured company shares.
    biopharma_dive · 5mo ago
  • OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
    Lung cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.
    onclive · 6mo ago
view all news mentions →
brand
Tevimbra
trade names
Tevimbra, Tizveni
generic
tislelizumab-jsgr
MOA
Programmed cell death protein 1 inhibitor
indication
Small-Cell Lung Cancer
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 3h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?